Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview.
The worldwide experience to date with VAQTA, a highly purified formalin-inactivated hepatitis A vaccine containing alum-adjuvant, is reviewed. No serious adverse experience related to vaccination has been reported. The vaccine has proven highly immunogenic, with seroconversion detectable after a single dose in 90-99% of children 2-16 years old, and of adults under 77 kg (170 lb) body weight. There is a trend toward lower one-dose seroconversion rates with increasing age and with weight > 77 kg. Early seroconversion in the latter groups may require two 25-unit doses given 2, 4 or 8 weeks apart, or a higher priming dose. Seroconversion induced by this vaccine has been shown to signify protection from clinical hepatitis A disease. The few vaccines whose titers have waned to borderline levels responded anamnestically to a booster, suggesting that the vaccine induces an immune memory response and should provide long-term protection.
Nalin
D R
DR
Merck Research Laboratories, West Point, PA.
Kuter
B J
BJ
Brown
L
L
Patterson
C
C
Calandra
G B
GB
Werzberger
A
A
Shouval
D
D
Ellerbeck
E
E
Block
S L
SL
Bishop
R
R
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000096:biosynthesis; D006507:Hepatovirus; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000009:adverse effects / Q000627:therapeutic use*
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D007075:Immunoglobulin M; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines